CagriSema at ObesityWeek 2026: REDEFINE 9 results at lower doses
The amylin pathway is back in the spotlight this week. On 14 November 2026, Novo Nordisk announced primary results from the Phase 3 REDEFINE 9 clinical trial of CagriSema, a fixed-dose combination of cagrilintide and semaglutide given once a week. The results were presented at ObesityWeek 2026 in Washington, D.C., and published the same day in The Lancet Diabetes & Endocrinology.
- 14 November 2026
- Novo Nordisk announced primary REDEFINE 9 results, presented at ObesityWeek 2026 and published in The Lancet Diabetes & Endocrinology.
- 15 November 2026
- Novo Nordisk presented a follow-up analysis of REDEFINE 1 on participants who responded early.
- Status
- The CagriSema application was filed with the US FDA in December 2025 and is under review. A decision is expected in the fourth quarter of 2026.
- Source
- Official Novo Nordisk releases via PR Newswire, 14 and 15 November 2026.
What REDEFINE 9 studied
REDEFINE 9 enrolled 309 adults with obesity, or with overweight plus at least one related condition, without diabetes. The study ran for 68 weeks, and all participants also followed a lifestyle program.
What makes it interesting: this is the first Phase 3 trial to assess CagriSema at two dose levels below the dose filed with the FDA. Each dose level was compared with a comparison group that received no active substance.
The numbers reported
| How it was calculated | Middle dose | Lowest dose | Comparison group |
|---|---|---|---|
| If all participants stayed on treatment to the end | 20.7% | 21.0% | 2.0% |
| All participants, whatever happened during the study | 19.4% | 18.6% | 4.6% |
About half of CagriSema participants recorded a weight reduction of 20% or more: 51.3% at the middle dose and 48.3% at the lowest dose under the first calculation. Waist circumference came down by an average of 17.2 cm and 17.5 cm.
The release notes that the study was not designed to compare the two doses with each other, so the small gap between them is best read as equivalent results. The most frequently recorded complaints were digestive and mild to moderate, in line with earlier CagriSema studies.
REDEFINE 1 follow-up analysis: early response
A day later, on 15 November 2026, Novo Nordisk presented a follow-up analysis of REDEFINE 1, a 68-week study with 3,417 participants that used the dose filed with the FDA. CagriSema participants were grouped by their early response: those whose weight came down by at least 5% at week 8 were called early responders.
In total, 67.8% of CagriSema participants were early responders, with an average weight reduction of 25.4% at week 68. The group that responded more slowly recorded an average of 17.8%. The lead author stressed that these figures are hypotheses for further research, not a basis for changing treatment decisions. Individual responses vary, and every figure above is a study group average.
Why this matters for the amylin pathway
Cagrilintide is a long-acting amylin analog, while semaglutide acts on the GLP-1 receptor. The two reach satiety signals through different receptors, and REDEFINE 9 adds to the picture that this pairing works at more than one dose level. The molecule's profile is in Cagrilintide and the amylin pathway, and another name on the same pathway is covered in Eloralintide and the amylin pathway.
This year's ObesityWeek also brought news from another pathway. A summary of the retatrutide data presented at the same meeting is in the latest retatrutide data, November 2026.
Cagrilintide in the Peptivia catalog
CagriSema is Novo Nordisk's combination, pairing cagrilintide with semaglutide. In the Peptivia catalog, cagrilintide comes in a different pairing, Retatrutide + Cagrilintide in a single vial, so the study figures above belong to CagriSema. Why this pairing draws interest is covered in Retatrutide and Cagrilintide: why they are paired.
Details for each product are in the Peptivia catalog. If you have questions before ordering, our team is glad to help through Peptivia's official WhatsApp.
